Outreach Development Corporation is a licensed substance use treatment provider in Brentwood, NY, listed in the SAMHSA treatment directory. Outpatient care is offered, so clients can keep living at home between scheduled sessions. Buprenorphine (Suboxone) is offered to reduce opioid cravings and lower relapse and overdose risk. Naltrexone is used to support recovery from opioid or alcohol use disorder. The program treats co-occurring mental health conditions alongside addiction. The facility reports accepting Medicaid. Private health insurance is accepted. It serves young adults, adults, seniors.
Availability and current services change often. Call (888) 470-5244
and we will help you confirm openings, insurance, and next steps.
Levels of care
OutpatientOutpatient methadone/buprenorphine or naltrexone treatmentRegular outpatient treatment
Type of care
Substance use treatment
Medications
Buprenorphine used in TreatmentNaltrexone used in Treatment
Payment accepted
Federal, or any government funding for substance use treatment programsMedicareMedicaidFederal military insurance (e.g., TRICARE)Private health insuranceCash or self-paymentState-financed health insurance plan other than Medicaid
Ages served
Young AdultsAdultsSeniors
Accreditation
State substance use treatment agencyCommission on Accreditation of Rehabilitation Facilities (CARF)SAMHSA certification for opioid treatment program (OTP)Drug Enforcement Agency (DEA)
Free & confidential, 24/7
Not sure which program fits? Talk it through with someone who can help.
998 Crooked Hill Road, 1st and 2nd Floors, Building 5, Brentwood, NY 11717
Residential/24-hour residentialLong-term residentialShort-term residentialFederal, or any government funding for substance use treatment programsMedicare
Residential/24-hour residentialLong-term residentialShort-term residentialFederal, or any government funding for substance use treatment programsMedicaid
OutpatientOutpatient methadone/buprenorphine or naltrexone treatmentRegular outpatient treatmentFederal, or any government funding for substance use treatment programsMedicare